More Representative Vaginal Temperature Measurements With a Hyperthermia Pelotte During Hyperthermia Treatments for Gynaecological Cancer.

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorDr. G.H. (Henrike) Westerveld

About this trial

The goal of this comparative, cross over single centre study is to to determine whether the average measured vaginal temperature during hyperthermia treatment is (clinically) significant different with the use of a pelotte than with a standard vaginal probe. in 27 women treated with external beam radiotherapy and deep hyperthermie for gynaecological cancer.. The primary endpoint is measured average vaginal temperatures with pelotte versus a standard vaginal probe.

The secondary endpoints are: reproducibility of catheter placement, patient comfort, inter-fractional spread of the vaginal temperature and the average vaginal temperature at the tip (0 cm) and 2 cm from the tip with pelotte and a standard vaginal probe.

Participants will be treated at least two time with a pelotte and two times with a standard vaginal probe. Participants will be asked to fill in a short questionnaire three times per treatment (before, during and after treatment). A total of 12-15 questionnaires will be completed by the participants over the four to five treatments.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Women aged 18 or older diagnosed with gynaecological cancer

Indication for EBRT with DHT

Written informed consent

Disqualifiers

Any condition potentially interfering with the understanding of the study requirements, informed consent procedure and completion of questionnaires

If the vaginal lumen is <4 cm.

Trial design

Design model

Crossover

Treatments tested in this trial

  • Pelotte

    Device

    The pelotte is a medical device. It is a round rod made of PTFE - polytetrafluoroethylene (figure 3). The top 7 cm has a diameter of 20 mm and the bottom 13 cm has a diameter of 11 mm. One disposable catheter for temperature measurements will be attached to the pelotte with tape. This catheter will be placed ventrally on the pelotte. A thermometer will be placed in this catheter. This thermometer will measure the vaginal temperatures. A condom is then placed over the pelotte and the catheter before insertion into the patient. At least two treatment will be with pelotte and at least 2 with a standard vaginal probe.

Treatment groups

27 Participants
are divided into 2 treatment groups
Group A: Group 1Other 1 intervention
Group B: Group 2Other 1 intervention

Trial outcomes

Primary outcomes

1

• Average vaginal temperature during DHT treatments with pelotte and with a standard vaginal probe.

To compare if the average vaginal measured temperature is significant different with a pelotte versus the standard vaginal probe

Time frame
approximately seven weeks from the intake with the radiation oncologist to the last treatment administration

Secondary outcomes

1

Inter-fractional reproducibility of the catheter placement in depth and position with pelotte and with a standard vaginal probe.

For each treatment, the free length of the vaginal probe is measured from the outer labia to the probe tip. This distance is subtracted from 293 mm to determine the internal depth of the vaginal probe. In the control room, the depth is determined based on the temperature measurements. If the measured temperature falls below 36 degrees Celsius at a certain point (e.g., 8 cm from the tip), this point is considered the probe depth. These values are then compared to assess whether there is a difference in reproducibility between treatments using the pelotte and treatments using only a vaginal probe.

Time frame
Approximately seven weeks from the intake with the radiation oncologist to the last treatment administration
2

Inter-fractional variance in measured vaginal temperatures with pelotte and with a standard vaginal probe.

Time frame
Approximately seven weeks from the intake with the radiation oncologist to the last treatment administration.
3

Patient-reported comfort with pelotte and with a standard vaginal probe, as assessed using the 'Vragenlijst Hyperthermie Pelotte' questionnaire

Time frame
Approximately seven weeks from the intake with the radiation oncologist to the last treatment administration.
4

Average vaginal temperature at the measurement points of the tip (0 cm) and two cm from the tip of the catheter with pelotte and with a standard vaginal probe.

Time frame
Approximately seven weeks from the intake with the radiation oncologist to the last treatment administration.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Dr. G.H. (Henrike) Westerveld

Lead sponsor

Erasmus Medical Center

Sponsor institution